Researchers devised a new method for generating protease-activated pro-antibodies, which prevent side effects that occur when therapeutic antibodies bind targets in healthy cells instead of diseased ...

Advances in the development of monoclonal antibodies have led to new agents rapidly incorporated into standard lymphoma therapy. The characteristics of the target antigen and the properties of the ...

Two targets, double success. This is the logic behind a new approach that uses monoclonal antibody (MAb) pairs to fight cancer. The two MAbs in the pair have different specificities and form ...

Monoclonal antibody (mAb) therapeutics comprise one of the most rapidly growing drug classes, with over 100 mAbs approved for use by the US FDA. The success of mAbs as a class of therapeutics is ...

In the past, product characterization was simple and standardized. Developers of small molecule pharmaceuticals performed a battery of tests around Phase II or III clinical trials, fulfilled the ...

Twist Biopharma employs synthetic DNA libraries against almost any antigen. The company creates large antibody libraries, which are then screened with high-throughput SPR technology from Carterra to ...

- Among 14 efficacy-evaluable patients in the ongoing Phase 1 study, one achieved a complete response, one had partial response and two unconfirmed partial responses; maximum tolerated dose not yet ...